NEW YORK, June 15 (Reuters) - Teva Pharmaceutical units Teva Pharmaceutical Finance III and Teva Pharmaceutical Finance BV on Tuesday sold $2.5 billion of debt in three parts, said IFR, a Thomson Reuters service.
Teva Pharmaceutical Finance III sold included $500 million of 18-month floating-rate, due Dec. 19, 2011, with a coupon rate of 40 basis points over the three-month Libor.
It also sold $1 billion of 1.50 percent two-year notes, due June 15, 2012, priced at 99.902 to yield 1.550 percent, or 80 basis points more than comparable U.S. Treasuries.
Teva Pharmaceutical Finance BV sold $1 billion of 3.00 percent, five-year notes, due June 15, 2015, priced at 99.876 to yield 3.02 percent or 95 basis points over Treasuries.
The active joint lead managers of the sale were Credit Suisse, Goldman Sachs and Morgan Stanley.
(Reporting by Pam Niimi) Keywords: TEVA DEBT/SALE (pam.niimi@thomsonreuters.com; +1-646-223-6321; Reuters Messaging: pam.niimi.reuters.com@reuters.net) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
Teva Pharmaceutical Finance III sold included $500 million of 18-month floating-rate, due Dec. 19, 2011, with a coupon rate of 40 basis points over the three-month Libor.
It also sold $1 billion of 1.50 percent two-year notes, due June 15, 2012, priced at 99.902 to yield 1.550 percent, or 80 basis points more than comparable U.S. Treasuries.
Teva Pharmaceutical Finance BV sold $1 billion of 3.00 percent, five-year notes, due June 15, 2015, priced at 99.876 to yield 3.02 percent or 95 basis points over Treasuries.
The active joint lead managers of the sale were Credit Suisse, Goldman Sachs and Morgan Stanley.
(Reporting by Pam Niimi) Keywords: TEVA DEBT/SALE (pam.niimi@thomsonreuters.com; +1-646-223-6321; Reuters Messaging: pam.niimi.reuters.com@reuters.net) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.